In this study previously untreated patients with chronic hepatitis C will receive high induction dose of IFN combined with Ribavirin and Amantadine for 6 weeks. Subsequently IFN is replaced by Peg IFN combined with Ribavirin and Amantadine. The…
ID
Bron
Verkorte titel
Aandoening
chronic hepatitis C
Ondersteuning
Academic Medical Center, University of Amsterdam
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Sustained virological response (HCV RNA undetectable 24 weeks after cessation of treatment).
Achtergrond van het onderzoek
In this study previously untreated patients with chronic hepatitis C will receive high induction dose of IFN combined with Ribavirin and Amantadine for 6 weeks. Subsequently IFN is replaced by Peg IFN combined with Ribavirin and Amantadine.
The aim of the study is to determine with the above treatment schedule, if a higher SVR rate can be achieved in patients with genotype 1 or 4 and to establish if the drop in viral load in the first 4 weeks of treatment is predictive for SVR.
Doel van het onderzoek
In this study previously untreated patients with chronic hepatitis C will receive high induction dose of IFN combined with Ribavirin and Amantadine for 6 weeks. Subsequently IFN is replaced by Peg IFN combined with Ribavirin and Amantadine.
The aim of the study is to determine with the above treatment schedule, if a higher SVR rate can be achieved in patients with genotype 1 or 4 and to establish if the drop in viral load in the first 4 weeks of treatment is predictive for SVR.
Onderzoeksopzet
N/A
Onderzoeksproduct en/of interventie
All patients will be treated for 24 or 48 weeks. Patients who achieve a 3log drop in viral load after 4 weeks of treatment will be randomized to stop treatment early after 24 weeks or continue to 48 weeks. Patients who do not achieve a 3 log drop after 4 weeks of treatment will be treated for 48 weeks. Patients who are HCV RNA positive at week 24 will stop treatment.
Publiek
719 Umbilo Road
Durban 4001
Huub C. Gelderblom
[default]
Zuid-Afrika
+27-31-2604072
gelderblom@ukzn.ac.za
Wetenschappelijk
719 Umbilo Road
Durban 4001
Huub C. Gelderblom
[default]
Zuid-Afrika
+27-31-2604072
gelderblom@ukzn.ac.za
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Patients which are serum HCV-RNA positive by PCR and with genotype 1 or 4;
2. Patients who never have used antiviral therapy for chronic hepatitis C;
3. Male and female patients >= 18 and < 65 years of age;
4. Patients who have given written informed consent after a detailed explanation of the study by the investigator.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Patients who are pregnant and patients (male or female) who are not willing to practice adequate contraception during the treatment period and up to 6 months after ending the treatment period;
2. Patients who are HBsAg or HIV antibody positive or who are unwilling to have these tests done;
3. Patients with decompensated cirrhosis (e.g. albumin < 32g/L, PTT prolonged > 4 s, bilirubin 2x > upper limit of normal, AT III < 60%, ascites, GI bleeding, encephalopathy);
4. Patients with a history of i.v. drug use within 6 months prior to entry;
5. Patients with any clinically significant systemic disease other than liver disease (e.g. malignant disease, congestive heart failure, uncontrolled diabetes mellitus, renal failure (serum creatinine > 181 micromol/ml), or autoimmmune disease;
6. Patients with a history of auto-immune hepatitis;
7. Patients using immune modulating treatment during the 6 months prior to study entry;
8. Patients with a history of hypersensitivity to any component of the study drugs;
9. Patients with pre-existing bone marrow depression such as hematocrit < 32%, white blood cell count < 3.0x10E9/L, granulocytes < 1.5x10E9/L, platelets < 100x10E9/L neutrophil count < 1.5x10E9 or Hemoglobin < 8.1 mmol/L for males and < 7.0 mmol/L for females;
10. Patients with severe depression or other psychiatric illness;
11. Patients with a history of epilepsy, or other clinically significant CNS dysfunction;
12. Patients with any condition, that in the opinion of the investigator, might interfere with the outcome of the study.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL517 |
| NTR-old | NTR560 |
| Ander register | : N/A |
| ISRCTN | ISRCTN59358441 |